Related Experiment Videos
Recombinant leukocyte interferon treatment of chronic hepatitis B
Insights
Recombinant leukocyte interferon therapy showed limited success in treating chronic hepatitis B carriers. While some patients achieved sustained viral marker loss, only 28.5% lost HBsAg, suggesting a need for precise carrier identification.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B remains a significant global health concern.
- Hepatitis B e-antigen (HBeAg), hepatitis B virus (HBV) DNA, and DNA polymerase are key viral markers.
- Recombinant leukocyte interferon (alpha-Interferon) has been explored for antiviral therapy.
Purpose of the Study:
- To evaluate the efficacy of a prolonged course of recombinant leukocyte interferon in chronic hepatitis B carriers.
- To identify factors associated with a positive treatment response.
Main Methods:
- A 9-week treatment course of recombinant leukocyte interferon was administered to 14 chronic hepatitis B virus carriers.
- Patients were positive for HBsAg, HBeAg, HBV DNA, and DNA polymerase.
- A control group of 11 untreated carriers was monitored concurrently.
Main Results:
- Six of 14 treated carriers achieved sustained loss of HBeAg, HBV DNA, and DNA polymerase.
- Four treated carriers (28.5%) subsequently lost HBsAg.
- Factors like elevated SGPT, chronic active hepatitis, treatment-induced SGPT increase, and recent carrier onset correlated with viral replication inhibition.
Conclusions:
- Recombinant leukocyte interferon therapy demonstrated restricted efficacy in chronic hepatitis B carriers.
- A sustained loss of viral markers was observed in a subset of patients.
- Therapeutic benefit may be limited to specific carrier populations requiring precise identification, potentially linked to host immune response.
Abstract:
We have investigated the efficacy of a relatively prolonged course of recombinant leukocyte interferon treatment in 14 chronic HBsAg-, HBeAg-, hepatitis B virus DNA- and DNA polymerase-positive carriers. alpha-Interferon was administered for 9 weeks. Six of 14 treated carriers have a sustained loss of HBeAg, hepatitis B virus DNA and DNA polymerase. Four subsequently lost HBsAg (28.5%). Elevated pretreatment SGPT concentrations, histologic chronic active hepatitis, an exacerbation of chronic hepatitis with an increase in SGPT concentrations in the last weeks of treatment and possibly recent onset of the carrier state was associated with complete inhibition of viral replication. None of 11 matched, untreated HBsAg-, HBeAg-, hepatitis B virus DNA- and DNA polymerase-positive carriers monitored during the same period lost HBsAg. The effect of recombinant leukocyte interferon may require an appropriate host-immune response. The efficacy of recombinant leukocyte interferon therapy is restricted, but it may be of benefit in a proportion of carriers, if these carriers can be precisely identified.